Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe.
In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010, which is being developed to treat dyskinesia in Parkinson’s disease, in a number of European countries, and the progress is cruising as company expected.
JM-010 is a new drug candidate developed by Bukwang’s subsidiary, Contera Pharma, Copenhagen based CNS focused bioventure, to treat dyskinesia in Parkinson’s disease patients. Dyskinesia is an inevitable symptom that occurs to ~90% of patients who take levodopa.
Currently, there is no treatment available in Europe, therefore not only investigators but also patients show strong interest in this clinical study.
Bukwang representative said, “Beginning with the first patient dosing, the company will speed up the clinical study by enrolling more patients, and eventually make LID treatment available to Parkinson’s patients.”
JM-010 phase 2 clinical study in Europe is cruising, and expecting to have results in 2021.
